{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-076682","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.076365+00:00","generated_at":"2026-06-17T21:25:04.755498+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"UroGen Pharma reports FY2022 JELMYTO revenue of $64.4M (+34% YoY); guides FY2023 revenue $76-86M","bullets":["JELMYTO net revenue for FY2022: $64.4M, up 34% from $48.0M in FY2021; Q4 revenue: $18.1M.","Net loss for FY2022: $109.2M ($4.79/share) vs $110.8M ($4.96/share) in FY2021; cash ~$100M.","UGN-102 Phase 3 ENVISION fully enrolled (~220 patients); topline data for ENVISION and ATLAS expected mid-2023; NDA submission targeted for 2024.","FY2023 guidance: JELMYTO revenue $76-86M; operating expenses $135-145M; cash expected to fund operations into H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-076682","json":"https://secwatch.observer/filing/0001193125-23-076682.json","markdown":"https://secwatch.observer/filing/0001193125-23-076682.md","text":"https://secwatch.observer/filing/0001193125-23-076682.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523076682/0001193125-23-076682-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523076682/d680885d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:25:04.755498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09e722761b81ae97555d6359a59389d761816c92","claim":"UroGen Pharma Ltd. reported the full year ended December 31, 2022 results: revenue $64.4 million.","evidence_excerpt":"Net product revenues were $64.4 million for the full year 2022, compared to $48.0 million for the full year 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523076682/0001193125-23-076682-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"$64.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7ad86edbc4e4fae0730be513093e99676451fdea","claim":"UroGen Pharma Ltd. reported the fourth quarter ended December 31, 2022 results: revenue $18.1 million.","evidence_excerpt":"UroGen reported JELMYTO net product revenues for the fourth quarter 2022 of $18.1 million, compared to $16.2 million for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523076682/0001193125-23-076682-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$18.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}